NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, highlighting continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. The company also outlined progress in its orphan-first regulatory strategy, including FDA orphan drug designation for measles granted subsequent to the quarter and additional applications targeting MPox and smallpox. To view the full press release, visit https://ibn.fm/osO0q.
NV-387 is a nanoviricide drug candidate designed as a broad-spectrum antiviral, with planned development for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as MPox, smallpox, and measles. The company’s orphan-first regulatory approach aims to expedite development for diseases with unmet medical needs. Obtaining FDA orphan drug designation for measles, along with pending applications for MPox and smallpox, could provide market exclusivity and development incentives. This strategy is particularly relevant given the resurgence of measles and the global need for treatments against poxviruses.
The company’s lead candidate NV-387 (API) is also the basis for NV-CoV-2, a nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, and NV-CoV-2-R, which encapsulates remdesivir within polymeric micelles. NanoViricides believes that since remdesivir is already FDA-approved, NV-CoV-2-R could be an approvable drug if safety is comparable. The company’s platform technology, licensed from TheraCour Pharma, Inc., enables the creation of targeted nanomaterials for antiviral therapy.
NanoViricides holds exclusive licenses for several antiviral drugs targeting HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses. The company intends to obtain licenses for RSV, poxviruses, and enteroviruses if initial research is successful. As with any drug development, the path to market is lengthy and requires substantial capital, with no assurance of clinical success.
For more information on NanoViricides, visit https://ibn.fm/NNVC. The latest news and updates are available in the company’s newsroom.
